AU2020254420A1 - Methods for production of CAR-NK cells and use thereof - Google Patents

Methods for production of CAR-NK cells and use thereof Download PDF

Info

Publication number
AU2020254420A1
AU2020254420A1 AU2020254420A AU2020254420A AU2020254420A1 AU 2020254420 A1 AU2020254420 A1 AU 2020254420A1 AU 2020254420 A AU2020254420 A AU 2020254420A AU 2020254420 A AU2020254420 A AU 2020254420A AU 2020254420 A1 AU2020254420 A1 AU 2020254420A1
Authority
AU
Australia
Prior art keywords
cells
car
cell
polypeptides
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020254420A
Other languages
English (en)
Inventor
Enli LIU
Katy REZVANI
Elizabeth SHPALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2020254420A1 publication Critical patent/AU2020254420A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2020254420A 2019-03-29 2020-03-25 Methods for production of CAR-NK cells and use thereof Pending AU2020254420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826856P 2019-03-29 2019-03-29
US62/826,856 2019-03-29
PCT/US2020/024671 WO2020205359A1 (en) 2019-03-29 2020-03-25 Methods for production of car-nk cells and use thereof

Publications (1)

Publication Number Publication Date
AU2020254420A1 true AU2020254420A1 (en) 2021-11-11

Family

ID=72667448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020254420A Pending AU2020254420A1 (en) 2019-03-29 2020-03-25 Methods for production of CAR-NK cells and use thereof

Country Status (13)

Country Link
US (1) US20220325245A1 (enExample)
EP (1) EP3947647A4 (enExample)
JP (1) JP2022519935A (enExample)
KR (1) KR20220004992A (enExample)
CN (1) CN113811604A (enExample)
AR (1) AR118510A1 (enExample)
AU (1) AU2020254420A1 (enExample)
BR (1) BR112021019411A2 (enExample)
CA (1) CA3135407A1 (enExample)
CO (1) CO2021012719A2 (enExample)
MX (1) MX2021011816A (enExample)
TW (1) TW202104252A (enExample)
WO (1) WO2020205359A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
KR20210005240A (ko) * 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
GB202005216D0 (en) * 2020-04-08 2020-05-20 Autolus Ltd Cell
US20240325443A1 (en) * 2021-07-23 2024-10-03 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN116262793A (zh) * 2021-12-13 2023-06-16 上海恒润达生生物科技股份有限公司 膜整合型融合蛋白、含有其的细胞及用途
CA3244259A1 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods for modulating the immune system
CN115896016B (zh) * 2022-09-07 2023-09-12 普华赛尔生物医疗科技有限公司 培养组合物及其在培养免疫细胞中的应用
WO2024058589A1 (ko) * 2022-09-16 2024-03-21 한국과학기술연구원 유전자 가위 넉-인을 이용하여 제조한 키메릭 항원 수용체 세포 및 이의 용도
IL320156A (en) * 2022-10-10 2025-06-01 Kite Pharma Inc New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection
CN116168765B (zh) * 2023-04-25 2023-08-18 山东大学 基于改进strobemer的基因序列生成方法及系统
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025006799A1 (en) * 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116769722B (zh) * 2023-07-04 2024-07-16 杭州荣谷生物科技有限公司 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用
CN121889169A (zh) * 2023-09-25 2026-04-17 南京传奇生物科技有限公司 经修饰的免疫细胞和钙调磷酸酶抑制剂及其用途
WO2025169136A1 (en) * 2024-02-09 2025-08-14 Takeda Pharmaceutical Company Limited Dosing regimen for cd19 car nk cells in treating cancer
US20250333700A1 (en) * 2024-02-28 2025-10-30 Gene Solutions Joint Stock Company Modified k562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1245080A1 (zh) * 2014-10-27 2018-08-24 University Of Central Florida Research Foundation, Inc. 自然杀伤细胞的方法和组合物
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
CN107868791B (zh) * 2016-09-26 2021-11-23 阿思科力(苏州)生物科技有限公司 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
EP3755347B1 (en) * 2018-02-21 2025-06-25 Board of Regents, The University of Texas System Universal antigen presenting cells and uses thereof
KR20210005240A (ko) * 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
EP3790958A1 (en) * 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells

Also Published As

Publication number Publication date
TW202104252A (zh) 2021-02-01
JP2022519935A (ja) 2022-03-25
US20220325245A1 (en) 2022-10-13
KR20220004992A (ko) 2022-01-12
BR112021019411A2 (pt) 2021-11-30
MX2021011816A (es) 2021-10-22
CN113811604A (zh) 2021-12-17
AR118510A1 (es) 2021-10-20
EP3947647A4 (en) 2023-01-04
CA3135407A1 (en) 2020-10-08
EP3947647A1 (en) 2022-02-09
WO2020205359A1 (en) 2020-10-08
CO2021012719A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
US20220325245A1 (en) Methods for production of car-nk cells and use thereof
US20260102335A1 (en) Immune cells expressing engineered antigen receptors
US12600944B2 (en) Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
US20210230548A1 (en) Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
US20220288121A1 (en) Cell cryopreservation medium
US20220389383A1 (en) Large-scale combined car transduction and crispr gene editing of nk cells
US20220033778A1 (en) Methods for ex vivo expansion of natural killer cells and use thereof
CA3162900A1 (en) Large-scale combined car transduction and crispr gene editing of b cells
EP4521919A1 (en) Cryopreservation of nk cell products for off-the-shelf immunotherapy
RU2846770C2 (ru) Способы получения car-nk-клеток и их применение
EA048895B1 (ru) Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
AU2020393906A1 (en) Large-scale combined car transduction and CRISPR gene editing of T cells